Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Public health policy and health economics

1550 - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs.

Date

11 Sep 2017

Session

Public health policy and health economics

Topics

Bioethical Principles and GCP

Presenters

Consolacion Molto Valiente

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

C. Molto Valiente1, A. Tibau1, A. Ocana Fernandez2, A. Templeton3, L. del Carpio Huerta1, J. Del Paggio4, A. Barnadas1, C. Booth5, E. Amir6

Author affiliations

  • 1 Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, 8026 - Barcelona/ES
  • 2 Medical Oncology Department And Translational Research Unit, Albacete University Hospital, Albacete/ES
  • 3 Department Of Medical Oncology, St Claraspital and Faculty of Medicine, University of Basel, Basel/CH
  • 4 Division Of Cancer Care And Epidemiology, Queen’s University Cancer Research Institute, Kingston/CA
  • 5 Departments Of Oncology And Public Health Sciences, Queen’s University Cancer Research Institute, K7L 3N6 - Kingston/CA
  • 6 Division Of Medical Oncology & Hematology, Department Of Medicine, Princess Margaret Cancer Centre and the University of Toronto, M5G 2M9 - Toronto/CA
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1550

Background

The Orphan Drug Act provides incentives to manufacturers to develop drugs for rare diseases. The ESMO-MCBS is a validated tool, aimed at quantifying the clinical benefit for cancer drugs. Here, we compare the characteristics of clinical trials leading to approval by the FDA of orphan and non-orphan drugs and apply the ESMO-MCBS thresholds for meaningful clinical benefit.

Methods

We searched the Drugs@FDA website to identify anticancer drugs approved between January 2006 and December 2016. These were then categorized as orphan or non-orphan drugs as determined by the FDA. For each drug, we subsequently collected data on clinical trial design and methodology and compared these between orphan and non-orphan drugs. For drugs supported by randomized controlled trials (RCTs), we applied a ESMO-MCBS grade. Comparisons were performed using Mann Whitney U or Chi squared tests.

Results

Of the 137 studies included, 109 (80%) were RCTs. These led to the approval of 63 individual drugs for 118 indications. Among these indications, 54 (46%) received orphan drug designation. Compared to non-orphan drugs, trials supporting orphan drugs approval had a smaller sample size (median 369 vs 687, P=.001), were less likely to evaluate experimental cytotoxic chemotherapy or endocrine therapy than targeted therapy (8% vs 21%, P=.005) were less often randomized (73% vs 86%; P=.047) and were more likely to assess intermediate endpoints rather than overall survival (71% vs 51%, P=.01). A similar proportion of orphan and non-orphan drugs approved for palliative use met the ESMO-MCBS threshold for meaningful benefit (29% vs 27%; P=.86). There were too few studies performed in the curative setting (n = 7) to perform statistical testing.

Conclusions

Compared with trials used to approve non-orphan cancer drugs, trials for orphan drugs are smaller, more likely to explore experimental biological therapies, use single-arm trials and intermediate end points. A similarly low proportion of approved orphan and non-orphan drugs meet the ESMO-MCBS threshold for meaningful benefit.

Clinical trial identification

Not applicable

Legal entity responsible for the study

None

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.